GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Geovax Labs Inc (NAS:GOVX) » Definitions » Cash Flow from Investing

Geovax Labs (Geovax Labs) Cash Flow from Investing : $-0.05 Mil (TTM As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Geovax Labs Cash Flow from Investing?

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

For the three months ended in Dec. 2023, Geovax Labs spent $0.02 Mil on purchasing property, plant, equipment. It gained $0.00 Mil from selling property, plant, and equipment. It spent $0.00 Mil on purchasing business. It gained $0.00 Mil from selling business. It spent $0.00 Mil on purchasing investments. It gained $0.00 Mil from selling investments. It paid $0.00Mil for net Intangibles purchase and sale. And it paid $0.00 Mil for other investing activities. In all, Geovax Labs spent $0.02 Mil on investment activities in financial market and operating subsidiaries for the three months ended in Dec. 2023.


Geovax Labs Cash Flow from Investing Historical Data

The historical data trend for Geovax Labs's Cash Flow from Investing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Geovax Labs Cash Flow from Investing Chart

Geovax Labs Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Flow from Investing
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.01 -0.16 -0.05 -0.13 -0.05

Geovax Labs Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cash Flow from Investing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - -0.02 -0.01 -0.02

Geovax Labs Cash Flow from Investing Calculation

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

If a company spends cash on property, plant and equipment (PPE), this will reduce their cash position. This is called Capital Expenditures (CPEX).

Likewise, if a company buys another company for cash, this will reduce their cash position.

Geovax Labs's Cash Flow from Investing for the fiscal year that ended in Dec. 2023 is calculated as:

Geovax Labs's Cash Flow from Investing for the quarter that ended in Dec. 2023 is calculated as:


Cash Flow from Investing for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.05 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Geovax Labs  (NAS:GOVX) Cash Flow from Investing Explanation

Cash flow from investing contains nine items:

1. Purchase Of Property, Plant, Equipment:
Purchase of PPE indicates the amount used to purchase property, plant, and equipment.

Geovax Labs's purchase of property, plant, equipment for the three months ended in Dec. 2023 was $-0.02 Mil. It means Geovax Labs spent $0.02 Mil on purchasing property, plant, equipment.

In the capital spending for property, plant and equipment (PPE), some part of spending may be from the expansion of business. The business needs more property, plant and equipment (PPE) as it grows. Another part may be from replacement of the property, plant and equipment (PPE) of existing business. For some companies, the cash spent on replacing of the property, plant and equipment (PPE) of the existing business will be close to the depreciation of property, plant and equipment (PPE) reported in the income statement.

In Warren Buffett's definition of Owner's Earnings, he deducts the estimate of the cost of replacing the property, plant and equipment (PPE) of the existing business from cash flow from operations. The cash spent on the new property, plant, and equipment is not deducted. The reason is because these are not costs of the existing business. In his 1986 letter to shareholders, Warren Buffett wrote this about owner earnings:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume....Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

2. Sale Of Property, Plant, Equipment:
Sale of PPE indicates the amount gained from selling property, plant, and equipment.

Geovax Labs's sale of property, plant, equipment for the three months ended in Dec. 2023 was $0.00 Mil. It means Geovax Labs gained $0.00 Mil from selling property, plant, and equipment.

3.Purchase Of Business:
Purchase of business indicates the amount used to purchase business.

Geovax Labs's purchase of business for the three months ended in Dec. 2023 was $0.00 Mil. It means Geovax Labs spent $0.00 Mil on purchasing business.

4. Sale Of Business:
Sale of business indicates the amount gained from selling business.

Geovax Labs's sale of business for the three months ended in Dec. 2023 was $0.00 Mil. It means Geovax Labs gained $0.00 Mil from selling business.

5. Purchase Of Investment:
Purchase of Investments represents cash outflow on the purchase of investments in securities.

Geovax Labs's purchase of investment for the three months ended in Dec. 2023 was $0.00 Mil. It means Geovax Labs spent {stock_data.stock.currency_symbol}}0.00 Mil on purchasing investments.

6. Sale Of Investment:
Sale of Investments represents cash inflow on the sale of investments in securities.

Geovax Labs's sale of investment for the three months ended in Dec. 2023 was $0.00 Mil. It means Geovax Labs gained $0.00 Mil from selling investments.

7. Net Intangibles Purchase And Sale:
Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.

Geovax Labs's net Intangibles purchase and sale for the three months ended in Dec. 2023 was $0.00 Mil. It means Geovax Labs paid $0.00 Mil for net Intangibles purchase and sale.

8. Cash From Discontinued Investing Activities:
Cash from discontinued investing activities means the cash received by a company that comes from the discontinued investing activities.

Geovax Labs's cash from discontinued investing activities for the three months ended in Dec. 2023 was 0.00 Mil. It means Geovax Labs paid $0.00 Mil for discontinued investing activities.

9. Cash From Other Investing Activities:
Cash from other investing activities means the cash received by a company that comes from other investing activities.

Geovax Labs's cash from other investing activities for the three months ended in Dec. 2023 was $0.00 Mil. It means Geovax Labs paid $0.00 Mil for other investing activities.


Geovax Labs Cash Flow from Investing Related Terms

Thank you for viewing the detailed overview of Geovax Labs's Cash Flow from Investing provided by GuruFocus.com. Please click on the following links to see related term pages.


Geovax Labs (Geovax Labs) Business Description

Traded in Other Exchanges
Address
1900 Lake Park Drive, Suite 380, Smyrna, GA, USA, 30080
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax's product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors.
Executives
Mckee Kelly T. Jr. officer: Chief Medical Officer 233 VALLEY MEADOW DRIVE, CHAPEL HILL NC 27516
David A Dodd director C/O SEROLOGICALS CORP, 5565 SPALDING DR, NORCROSS GA 30092
Mark Reynolds officer: Chief Financial Officer TWO BALA PLAZA, SUITE 300, PHILADELPHIA PA 19004
Jayne Morgan director 1900 LAKE PARK DRIVE, SUITE 380, SMYRNA GA 30080
Randal D Chase director 28 GEORGIA COURT, RICHMOND HILL A6 L4E ON7
Nicole Lemerond director 3 MURRAY HILL ROAD, SCARSDALE NY 10583
John W. Sharkey officer: VP, Business Development 16857 E. SAGUARO BLVD., FOUNTAIN HILLS AZ 85268
Dean G Kollintzas director 1256 BRIARCLIFF ROAD N.E., EMTECH BIO SUITE 500, ATLANTA GA 30306
Spencer John N Jr director 2859 PACES FERRY RD, STE 1000, ATLANTA GA 30339
Robert T Mcnally director
Farshad Guirakhoo officer: Sr VP, Research & Development 39 CHESTNUT STREET, MELROSE MA 02176
Steven S. Antebi director 10550 FONTENELLE WAY, LOS ANGELES CA 90077
Harriet L Robinson other: Chair, Scientific Adv Brd 1256 BRIARCLIFF ROAD N.E., EMTECH BIO SUITE 500, ATLANTA GA 30306
Mark J Newman officer: VP, Research & Development 1900 LAKE PARK DR, SUITE 380, SMYRNA GA 30080
Peter M Tsolinas director 123 JOAN DRIVE, BARRINGTON IL 60010